Table 2.
Studies of stem cell transplant in DHL.
| Authors and study type | Patients included | Progression-/relapse-/event-free survival (months) | Overall survival (months) |
|---|---|---|---|
| Peniket AJ et al. BMT 2003 Retrospective |
255 alloSCT for high-grade NHL | Median PFS: 7.1 months 4-year PFS: 39.3% |
Median OS: 1 year 4-year OS: 41.2% 4-year procedure-related mortality: 33.0% |
| Petrich AM et al. Blood 2014 Retrospective |
311 total patients: 286 DHL, 25 THL | Not reported for transplant patients: 83 total SCT patients including 39 autoSCT and 14 alloSCT in CR1 | Median OS: Observation with CR1: 103 months Consolidation SCT (any type): not reached (p=0.14) Auto- or allo-SCT in CR1: not reached (p=0.302) |
| Oki Y et al. BJH 2014 Retrospective |
129 DHL: 71 achieved CR1 23 SCT in CR1 |
EFS all stages achieving CR, frontline SCT: HR 0.53 (95% CI: 0.21–1.31, p=0.170) EFS advanced stage achieving CR, frontline SCT: HR 0.42 (95% CI: 0.17–1.05, p=0.065) |
All stages achieving CR, frontline SCT: HR 0.74 (95% CI: 0.27–2.04, p=0.566) Advanced stage achieving CR, frontline SCT: HR 0.58 (95% CI: 0.21–1.60, p=0.292) |
| Landsburg DJ et al. JCO 2017 Retrospective |
159 DHL: 62 AutoSCT in CR1 27 R-CHOP/Non-AutoSCT 8 R-CHOP/AutoSCT 70 Intensive/Non-AutoSCT 54 Intensive/AutoSCT |
3-year RFS: All patients: 80% AutoSCT in CR1: 75% Non-AutoSCT: 89% R-CHOP/Non-AutoSCT: 51% R-CHOP/AutoSCT in CR1: 75% Intensive Regimen/Non-AutoSCT CR1: 86% (p=0.002, compared with R-CHOP) Intensive Regimen/AutoSCT CR1: 91% |
3-year OS (No significant difference): All patients: 87% AutoSCT in CR1: 85% Non-AutoSCT: 91% R-CHOP/non-autoSCT: 75% R-CHOP/autoSCT in CR1: 83% Intensive regimen/non-autoSCT CR1: 89% Intensive regimen/autoSCT CR1: 92% |
| Herrera AF et al. JCO 2017 Retrospective |
117 DLBCL s/p autoSCT: 52 DEL 12 DHL |
4-year PFS: Non-DEL/DHL: 60% (95% CI: 46–72) DEL: 48% (95% CI: 34–61) DHL: 28% (95% CI: 6–57, p=0.013) |
4-year OS: Non-DEL/DHL: 70% (95% CI: 55–80) DEL: 56% (95% CI: 40–69) DHL: 25% (95% CI: 5–54, p<0.001) |
| Chen AI et al. Leuk Lymph 2018 Retrospective |
36 DHL treated with DA-EPOCH-R 17 received autoSCT |
2-year PFS: 69% (95% CI: 54–84) 2-year PFS autoSCT: 94% (95% CI: 83–100) 2-year PFS observation: 79% (95% CI: 52–100) (p=0.59) |
2-year OS: 71% (95% CI: 56–86) 2-year OS autoSCT: 94% (95% CI: 83–100) 2-year PFS observation: 79% (95% CI: 52–100) (p=0.59) |
| Herrera AF et al. Biol BMT 2018 Retrospective |
78 total HGBL: 31 DEL 10 DHL |
4-year PFS: DHL: 40% (p=0.62) Non-DHL: 34% DEL: 30% (p=0.24) Non-DEL: 39% |
4-year OS: DHL: 50% (p=0.46) Non-DHL: 38% DEL: 31% (p=0.46) Non-DEL: 49% |
| Salhotra A et al. Biol BMT 2019 Retrospective |
22 patients with lymphoma s/p alloSCT: 10 DLBCL | 2-year EFS: 58.3% (95% CI: 35–75.8) 2-year cumulative incidence of relapse: 31.8% (95% CI: 13.6–51.8) |
2-year OS: 45.5% (95% CI: 24.4–64.3) 2-year non-relapse mortality: 27.7% (95% CI: 8.0–42.0) |
alloSCT, allogeneic stem cell transplant; autoSCT, autologous stem cell transplant; CI, confidence interval; CR, complete remission; CR1, first complete remission; DEL, double expressor lymphoma; DHL, double hit lymphoma; DLBCL, diffuse large B-cell lymphoma; EFS, event-free survival; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival; SCT, stem cell transplant.